Project Description

RSVP:

Please include area code (999) 555-1234

Every year tens of thousands of children and young adults are diagnosed with F.A.P., an inherited colorectal cancer syndrome. Emtora is developing the first every therapy for F.A.P. Join us to find out more about this exciting breakthrough.

Date & Time:

August 4, 12:00 PM EDT
Webinar: Details provided upon RSVP approval

About the Event:

Every year tens of thousands of children and young adults are diagnosed with F.A.P., an inherited colorectal cancer syndrome. With no cure and no approved therapy, 100% of patients with F.A.P. develop colorectal cancer by age 39. Currently the only treatment is surgery.
Emtora has created eRapa, a novel, encapsulated form of Rapamycin that has demonstrated effectiveness in Phase 1 clinical trials for F.A.P. In addition, eRapa has shown promise for treating prostate, bladder, and other forms of cancer.
With orphan drug status and a fast track designation in progress, eRapa has already been backed by the NIH, NCI, and state of Texas.
Join our webinar to learn more about the opportunities for eRapa from Emtora’s executive team.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.